{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-22-000020","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2022-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.386756+00:00","generated_at":"2026-06-24T11:52:49.150709+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biogen Q2 revenue $2.59B, GAAP EPS $7.24; raises full-year guidance","bullets":["Q2 total revenue $2,589M, down 7% YoY; MS revenue $1,719M (-4%), SPINRAZA $431M (-14%).","GAAP diluted EPS $7.24; Non-GAAP diluted EPS $5.25.","FDA granted Priority Review for lecanemab (Alzheimer's) with decision by Jan 6, 2023; Phase 3 data expected Fall 2022.","Second positive Phase 3 for zuranolone in PPD; joint U.S. filing for MDD and PPD expected H2 2022.","Launched BYOOVIZ (biosimilar Lucentis) in U.S.; raised full year 2022 financial guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-22-000020","json":"https://secwatch.observer/filing/0000875045-22-000020.json","markdown":"https://secwatch.observer/filing/0000875045-22-000020.md","text":"https://secwatch.observer/filing/0000875045-22-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504522000020/0000875045-22-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504522000020/biib-20220720.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T11:52:49.150709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}